https://webnewsinsider.com/the-1500-a-year-glp-1-drug-threat-to-retirement-savings/ WebNewsInsider en 2026-11-08T05:12:57+08:00 The $1,500-a-Year GLP-1 Drug Threat to Retirement Savings https://webnewsinsider.com/lenacapavir-prep-costs-42250-a-year-in-the-u-s-versus-60-for-generic-pills/ WebNewsInsider en 2026-11-08T00:11:37+08:00 Lenacapavir PrEP Costs $42,250 a Year in the U.S. Versus $60 for Generic Pills https://webnewsinsider.com/fda-approves-first-antisense-drug-offering-finite-hepatitis-b-therapy/ WebNewsInsider en 2026-11-07T23:12:40+08:00 FDA Approves First Antisense Drug Offering Finite Hepatitis B Therapy https://webnewsinsider.com/star-healths-%e2%82%b9780-crore-cancer-payouts-signal-rising-claims-burden-for-policyholders/ WebNewsInsider en 2026-11-07T23:11:31+08:00 Star Health’s ₹780 Crore Cancer Payouts Signal Rising Claims Burden for Policyholders https://webnewsinsider.com/how-missing-bank-statements-trigger-medicaid-denials-and-41000-bills-for-nursing-home-residents/ WebNewsInsider en 2026-11-07T21:11:03+08:00 How Missing Bank Statements Trigger Medicaid Denials and $41,000 Bills for Nursing Home Residents https://webnewsinsider.com/study-finds-autistic-adults-over-45-face-nearly-triple-parkinsonism-rates/ WebNewsInsider en 2026-11-07T17:12:35+08:00 Study Finds Autistic Adults Over 45 Face Nearly Triple Parkinsonism Rates https://webnewsinsider.com/why-former-firefighters-face-lingering-psychological-trauma-after-leaving-the-career/ WebNewsInsider en 2026-11-07T13:11:09+08:00 Why Former Firefighters Face Lingering Psychological Trauma After Leaving the Career https://webnewsinsider.com/overcoming-immunotherapy-resistance-takes-center-stage-at-sitc-2026/ WebNewsInsider en 2026-11-07T08:23:00+08:00 Overcoming Immunotherapy Resistance Takes Center Stage at SITC 2026 https://webnewsinsider.com/retirees-can-sidestep-new-senior-deduction-cliff-by-using-roth-withdrawals/ WebNewsInsider en 2026-11-07T08:22:03+08:00 Retirees Can Sidestep New Senior Deduction Cliff by Using Roth Withdrawals https://webnewsinsider.com/how-amivantamabs-dual-egfr-met-blockade-overcomes-resistance-in-head-and-neck-cancer/ WebNewsInsider en 2026-11-06T08:22:18+08:00 How Amivantamab’s Dual EGFR-MET Blockade Overcomes Resistance in Head and Neck Cancer